Inhaled Virus-Mimicking Particles Elicit Dose-Dependent Immune Response against SARS-CoV-2 with Sex-Bias ACE2 Activity in Mice.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42172552.
- Also identified by DOI 10.1021/acs.nanolett.5c05282.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There is an urgent need to develop antigen presentation platforms that can induce broadly systemic immunity against multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subvariants. Here, virus-mimicking particles (VMP) are functionalized with substantial receptor binding domain protrusions from Delta variant SARS-CoV-2 on particle surface, programmed by biotin-streptavidin interaction. The fabricated VMP reveal superior pulmonary biodistribution and retention for at least 1 day in C57BL/6 female mice after oropharyngeal aspiration exposure. VMP at higher dosage elicit a robust and broad systemic immune response against SARS-CoV-2 variants in K18 human angiotensin-converting enzyme 2 (ACE2) transgenic mice. Furthermore, ACE2 expression in males dramatically decreases after high-dose VMP inhalation, while that in females remains comparable to baseline, which might be the reason that females are less vulnerable to the adverse effects than males. Overall, VMP are a promising candidate for next-generation viral inhibitors and immune stimulating particles against current and future SARS-CoV-2 variants.